Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
Adding empagliflozin to recommended therapy in patients with heart failure with reduced ejection fraction (HFrEF) reduced the risk of HF hospitalization and slowed renal function decline, the EMPEROR-Reduced* trial showed.
In this final issue of our series, join us as we
look into the upcoming results of the pivotal EMPEROR trials, which will
investigate the use of empagliflozin in patients with either preserved or
reduced ejection fraction heart failure, with or without type 2 diabetes.
Understand why heart failure has such a high clinical burden, and the great
unmet need in providing solutions for it.
In this fourth issue,
join us as we discover the unique biology Asians have with respect to diabetes.
Take a closer look at trials evaluating whether empagliflozin’s cardiovascular
and renal benefits – as analysed in Asians – are consistent with the overall
trial population, and how it addresses unmet needs.
Hyperkalaemia (HK) occurrence and recurrence are frequent in advanced CKD*, creating a perfect storm for cardiovascular events and death, says Professor Juan-Jesus Carrero from the Karolinska Institute, Solna, Sweden, at ERA-EDTA 2020. Given these risks, acutely elevated potassium (K+) should merit clinical attention.
In this third issue we take
a look at how empagliflozin made a bold impact on clinical guidelines across
multiple specialties. We will explore how existing treatment recommendations
were altered, and summarise the current guidelines and future perspectives of
This second issue revisits the impact EMPA-REG OUTCOME had on clinical
practice and helps readers discover how it gives life back to patients
through its cardiovascular indication. Learn how it was approved and the
mechanisms for its cardiovascular benefits.
Dropping aspirin after 3 months of dual therapy with ticagrelor reduced bleeding in patients with diabetes who have undergone PCI* vs taking both agents for 1 year, the TWILIGHT-DM** study has shown, consistent with benefits seen in TWILIGHT for other high-risk patients.
Treatment with the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone reduced chronic kidney disease (CKD) progression and cardiovascular (CV) event risk in patients with CKD and type 2 diabetes (T2D), according to the FIDELIO-DKD* study presented at ASN Kidney Week 2020.